###begin article-title 0
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 123 126 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1</italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 338 345 <span type="species:ncbi:9606">patient</span>
The early to intermediate stages of the majority of colorectal tumours are thought to be driven by aberrations in the Wnt (APC, CTNNB1) and Ras (K-ras) pathways. A smaller proportion of cancers shows mismatch repair deficiency. The aim of this study was to analyse the co-occurrence of these genetic alterations in relation to tumour and patient characteristics.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 256 263 <span type="species:ncbi:9606">patient</span>
In a group of 656 unselected sporadic colorectal cancer patients, aberrations in the APC, K-ras, CTNNB1 genes, and expression of hMLH1 were investigated. Additionally, tumours were divided in groups based on molecular features and compared with respect to patient's age at diagnosis, sex, family history of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 666 670 666 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 677 683 677 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 452 460 <span type="species:ncbi:9606">Patients</span>
###xml 533 538 <span type="species:ncbi:9606">women</span>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
Mutations at the phosphorylation sites (codons 31, 33, 37, and 45) in the CTNNB1 gene were observed in tumours from only 5/464 patients. Tumours with truncating APC mutations and activating K-ras mutations in codons 12 and 13 occurred at similar frequencies (37% (245/656) and 36% (235/656), respectively). Seventeen percent of tumours harboured both an APC and a K-ras mutation (109/656). Nine percent of all tumours (58/656) lacked hMLH1 expression. Patients harbouring a tumour with absent hMLH1 expression were older, more often women, more often had proximal colon tumours that showed poorer differentiation when compared to patients harbouring tumours with an APC and/or K-ras mutation.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
CTNNB1 mutations seem to be of minor importance in sporadic colorectal cancer. The main differences in tumour and patient characteristics are found between groups of patients based on mismatch repair deficiency.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 457 460 457 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4</italic>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 495 501 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1</italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Carcinogenesis is a multi-step process that involves the accumulation of numerous genetic and epigenetic changes in cells [1]. These genetic aberrations affect a limited number of identified pathways that are involved in (colorectal) carcinogenesis [2]. A genetic model for sporadic colorectal cancer has been proposed, which describes the sequential accumulation of specific genetic alterations in various pathways, involving tumour suppressor genes (e.g. APC, SMAD4, TP53) and oncogenes (e.g. CTNNB1, K-ras) [3,4]. Important molecular pathways that upon activation affect the early and intermediate stages of colorectal carcinogenesis are the Wnt and Ras signalling pathways, whereas TP53 inactivation is considered a late event.
###end p 11
###begin p 12
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 288 289 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 290 291 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 331 335 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 346 347 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 461 468 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 841 847 835 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 853 854 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Activation of the Wnt pathway plays a central role in the aetiology of most colorectal cancers and is often the result of mutations in the N-terminal domain of the APC gene, that lead to partial or complete loss of this region and thereby to loss of the beta-catenin regulating function [5,6]. Conversely, in tumours lacking these APC mutations [7], activating missense mutations at one of the phosphorylation sites at codons 31, 33, 37 and 45 of exon 3 of the CTNNB1 gene (encoding the beta-catenin protein) can render it stable as it can no longer be tagged for cellular degradation. Activation of the Ras pathway in cancer is marked by the loss of the intrinsic GTPase activity of the Ras protein, which can be ascribed to missense mutations in codons 12 and 13 of exon 1, which are responsible for 90% activating mutations in the of the K-ras gene [8].
###end p 12
###begin p 13
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 227 230 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
According to the paradigm for colorectal cancer development, mutations in the APC and K-ras are thought to contribute to the early developmental stages of colorectal cancer [3]. However, a recent study based on the analysis of APC, K-ras and TP53 genes concluded that simultaneous occurrence of all three genetic alterations is rare and that multiple genetic pathways may be relevant to colorectal cancer [9].
###end p 13
###begin p 14
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 701 704 701 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 706 712 706 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 716 719 716 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP5</italic>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1186 1193 1186 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 1078 1083 <span type="species:ncbi:9606">women</span>
Genetic instability is seen in most types of cancer [10]. Two distinct types of genetic instability appear to occur in colorectal cancer [11]: chromosomal and microsatellite instability. Chromosomal instability results in gains or losses of entire chromosomes or parts of them, and gives rise to aneuploid tumours and occurs in the majority of cancers. A smaller proportion of colorectal cancers displays microsatellite instability, represented by diploid cells acquiring high mutation rates, and was found to be associated with defective mismatch repair [12]. These tumours are less likely to harbour mutations in genes associated with chromosomally instable and generally aneuploid tumours, such as APC, K-ras and TP53 [13-21], suggesting that these tumours form a distinct group. Moreover, microsatellite instable tumours are found predominantly in the proximal colon [22,23], are more likely to occur in patients with a positive family history of colorectal cancer [22,23], are often less differentiated than microsatellite stable tumours [22], and occur more frequently in women [24] and at older age [25]. Moreover, in tumours displaying microsatellite instability, mutations the CTNNB1 gene were more frequent [26].
###end p 14
###begin p 15
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 364 367 364 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 538 545 <span type="species:ncbi:9606">patient</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
Considering the aforementioned issues, there is a need for studies addressing the heterogeneity of affected genes involved in early to intermediate colorectal cancer development in large groups of patients. We have previously studied the occurrence of APC and K-ras mutations separately [27,28]. In the current study, in addition to investigating mutations in the APC, CTNNB1 and K-ras genes as well as mismatch repair deficiency by means of hMLH1 expression, and combinations of these aberrations, their relation with various tumour and patient characteristics were studied in a large, unselected group of incident colorectal cancer patients.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Study population
###end title 17
###begin p 18
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 287 290 <span type="species:ncbi:9606">men</span>
###xml 302 307 <span type="species:ncbi:9606">women</span>
The prospective Netherlands Cohort Study on diet and cancer was initiated in September 1986. The study design has been described in detail elsewhere [29]. The study population originated from 204 municipal population registries throughout the Netherlands, and included a total of 58,279 men and 62,573 women between the ages of 55 and 69 years at baseline.
###end p 18
###begin p 19
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Incident cancer cases are identified by monitoring of the entire cohort for cancer occurrence through annual record linkage to the Netherlands Cancer Registry, i.e. nine regional cancer registries throughout the Netherlands, and to PALGA, a nationwide network and registry of histo- and cytopathology [30]. Together, the NCR and PALGA provide a near 100% coverage of the municipalities included in the NLCS. The first 2.3 years of follow up were excluded because of possible pre-clinical disease affecting exposure status and because of incomplete nationwide coverage of PALGA in some of the municipalities included in the NLCS in that period. From 1989 until 1994, 929 incident cases with histologically confirmed colorectal cancer were identified within the cohort, of whom 819 could also be linked to a PALGA report of the lesion.
###end p 19
###begin p 20
###xml 97 105 <span type="species:ncbi:9606">patients</span>
The PALGA reports were used to identify and locate tumour tissue from eligible colorectal cancer patients in Dutch pathology laboratories. Colon and rectal cancer were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).
###end p 20
###begin title 21
Tissue samples
###end title 21
###begin p 22
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
Tumour material of colorectal cancer patients was collected after approval by the Ethical Review Board of Maastricht University, PALGA and the NCR. Tissue samples from 819 colorectal cancer patients were localized in 54 pathology laboratories throughout the Netherlands. Forty-four (5%) tumour tissue samples could not be retrieved from the pathology archives. Of 775 available tissue samples, 737 (95%) contained sufficient tumour material for molecular analyses. Tissue sections were cut from each sample, which were used for DNA isolation and immunohistochemical analysis.
###end p 22
###begin title 23
DNA isolation
###end title 23
###begin p 24
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
DNA isolation was described in detail elsewhere [27]. Briefly, a 4 mum section, cut from each paraffin-embedded tumour tissue block, was stained with haematoxylin and eosin (HE) for histopathological examination by a pathologist. Five 20 mum sections of tumour tissue were cut from each sample for DNA isolation. Tumour tissue was separated from normal colon epithelium using the HE section as a reference. Genomic DNA was extracted from macrodissected tumour tissue using proteinase K (Qiagen, St. Louis, MO, USA) and the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN, USA). DNA concentration and purity was measured at 260 and 280 nm.
###end p 24
###begin title 25
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
K-ras mutation analysis
###end title 25
###begin p 26
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Mutation analysis of the exon 1 fragment of the K-ras oncogene, spanning codons 8-29, was performed on archival colorectal adenocarcinoma specimens of 737 patients, using nested PCR, followed by direct sequencing of purified fragments [27]. The detection limit was 5% mutated DNA and duplicate experiments revealed a good reproducibility (88%) [27].
###end p 26
###begin title 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
APC mutation analysis
###end title 27
###begin p 28
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 631 639 <span type="species:ncbi:9606">patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
The majority of somatic mutations in the APC gene are found within the mutation cluster region (codons 1286-1520). Mutation analysis of the mutation cluster region was performed on adenocarcinoma DNA using nested PCR for amplification of the mutation cluster region as four overlapping DNA fragments followed by direct sequencing of purified fragments, as previously described [28]. An alternative nested PCR strategy was performed when nested PCR failed for any of the fragments, using different primers. The detection limit was 5% mutated DNA and duplicate experiments revealed good reproducibility (85%)[28]. From 72 of the 737 patients with sufficient DNA yield, one or more fragments of the mutation cluster region could not be amplified and these patients were not included in this study.
###end p 28
###begin title 29
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
CTNNB1 mutation analysis
###end title 29
###begin p 30
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 359 366 359 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 472 479 472 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
All 464 samples without a truncating APC mutation (n = 411) and all samples with absent hMLH1 expression (n = 58) were analysed for mutations in the phosphorylation sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1 gene. This selection was made, since most mutations are expected in these samples. Tumours lacking truncating APC mutations may harbour CTNNB1 mutations [7], and microsatellite instable tumours are also expected to more frequently have mutations in CTNNB1 [26].
###end p 30
###begin p 31
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
Amplification of exon 3 of the CTNNB1 gene entailed a semi-nested PCR strategy, which covered codons 33, 37, 41 and 45. Flank PCR was performed to generate a 308 bp fragment (primers, forward: 5'-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-GCATTCTGACTTTCAGTAAGGC-3') that was used in a 1:100 dilution for amplification of the final PCR product (primers, forward: 5'-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-CTTCCTCAGGATTGCCTTTACC-3'). In each PCR, one round of 35 cycles was performed.
###end p 31
###begin p 32
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
The semi-nested PCR products from samples without a truncating APC mutation were screened for mutations using denaturing high-pressure liquid chromatography (dHPLC) on a WAVE 3500 HT system (Transgenomic Inc., UK). WAVE analysis was optimised and validated using specific mutations in cell line DNA, i.e. HCT116 (codon 45: 3 bp deletion) and SW48 (codon 33: C-->A) as well as DNA derived from desmoid tumours from patients (codon 41: A-->G and codon 45: C-->T) as positive controls. All of these mutations were repeatedly confirmed by sequencing. WAVE analysis was carried out at two different temperatures (57.7 en 60degreesC). Samples showing an aberrant elution profile were re-amplified and re-screened. When an aberrant elution profile was confirmed, direct sequencing was performed. All samples without hMLH1 expression were analysed by direct sequencing without screening. The sequence profile was analysed on an ALFexpress II DNA analysis system using ALFwin software (Amersham Biosciences, Roosendaal, the Netherlands).
###end p 32
###begin title 33
hMLH1 expression
###end title 33
###begin p 34
###xml 208 209 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 210 211 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 325 330 <span type="species:ncbi:9796">horse</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
Formalin-fixed, paraffin-embedded tissue sections cut at 4 mum, which included tumour tissue with normal adjacent mucosa, were used for immunohistochemistry. Endogenous peroxidase activity was blocked by 3% H2O2. Slides were submitted to microwave antigen retrieval in 1 mM EDTA buffer (pH 8.0) and incubated with 10% normal horse serum for ten min at room temperature. Then, sections were incubated overnight at 4degreesC with mouse monoclonal antibodies against hMLH1 protein (clone G168-15, PharMingen, San Diego, CA) at a 1:100 dilution. Antibody binding was detected by incubating the sections at room temperature with the peroxidase-labelled DAKO Envision System (DAKO, Carpinteris, CA), using DAB as a chromogen. Sections were counterstained with diluted haematoxylin.
###end p 34
###begin p 35
###xml 461 469 <span type="species:ncbi:9606">patients</span>
Lesions were considered to lack hMLH1 protein expression when unequivocal absence of nuclear staining of the tumour epithelial cells was observed. Nuclear staining of normal epithelial and stromal cells or lymphocytes served as an internal positive control. Staining was scored independently by at least two observers and in case of discordant results discussed with a pathologist until consensus was reached. hMLH1 expression could be determined in 724 of 737 patients.
###end p 35
###begin title 36
BAT-26
###end title 36
###begin p 37
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Analysis of the BAT-26 mononucleotide repeat was performed in a random sample of tumour specimens from 114 patients, and a series of 48 of 58 tumours that lacked hMLH1 expression, to assess the concordance between the microsatellite instability marker BAT-26 and hMLH1 expression. The primer sequences and PCR conditions for the BAT-26 mononucleotide repeat were used as described previously [31].
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
In the statistical analysis, data from 656 patients for whom information on APC and K-ras mutation status as well as hMLH1 expression was complete were included.
###end p 39
###begin p 40
###xml 7 9 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 95 101 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 105 109 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 355 361 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 377 381 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 512 514 508 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 702 708 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 728 732 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 796 797 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 840 841 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 637 644 <span type="species:ncbi:9606">patient</span>
The chi2 test and Cramers V test were used to estimate the association of the co-occurrence of K-ras and APC gene mutations. Characteristics of patients (age at diagnosis, sex, family history of colorectal cancer) and tumours (tumour sub-localisation, Dukes' stage and tumour differentiation) were compared between patients with and without an activating K-ras or a truncating APC mutation as well as patients harbouring tumours with and without hMLH1 expression, using Students T-test (age at diagnosis) and chi2 tests (sex, family history of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation). Additionally, patient and tumour characteristics of tumours with an activating K-ras and/or a truncating APC mutation were compared to tumours lacking hMLH1 expression. All P-values are reported for a two-sided test; P-values of less than 0.05 were considered to be statistically significant.
###end p 40
###begin title 41
Results
###end title 41
###begin p 42
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 282 289 282 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 327 334 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 641 647 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 765 772 761 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 993 1000 989 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 1195 1199 1191 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1256 1263 1252 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 1274 1275 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 201 208 <span type="species:ncbi:9606">patient</span>
###xml 728 736 <span type="species:ncbi:9606">patients</span>
Tumours from 464 of 656 patients, which did not harbour a truncating APC mutation or lacked hMLH1 expression, were analysed for mutations in exon 3 of the CTNNB1 gene. Table 1 describes the tumour and patient characteristics of seven colorectal tumours that harboured a mutation in CTNNB1 exon 3. In five colorectal cancers, a CTNNB1 mutation that would lead to loss of one of the Ser/Thr phosphorylation sites and subsequent stabilisation of the protein, occurred at codons 37 and 45, all were C-->T transitions, leading to Ser-->Phe amino acid changes and occurred in the proximal colon. All bar one also had an activating mutation in the K-ras gene. Three of these five tumours showed hMLH1 deficiency. Two colorectal cancer patients harboured a mutation in the CTNNB1 gene, that did not occur at the Ser/Thr phosphorylation sites, but would result in an amino acid alteration at codons 22 and 29, the effects of which are unknown. Because of the very low frequency of tumours harbouring a CTNNB1 mutation, these mutations were not included in further analyses. In addition, mutation analysis of remaining samples was abandoned, since this was deemed irrelevant as these harboured truncating APC mutations and are considered to be unlikely to also have CTNNB1 mutations [7].
###end p 42
###begin p 43
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 648 652 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 789 790 789 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 921 923 919 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 963 967 961 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 994 1000 992 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 1081 1083 1077 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1090 1092 1086 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1214 1218 1210 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1221 1227 1217 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 1356 1358 1350 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1366 1368 1360 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Of 656 tumours for which the other molecular alterations, i.e. mutations in the APC and K-ras genes and hMLH1 expression, were all successfully and completely analysed, 103 colorectal tumours did not harbour a truncating or missense APC mutation, an activating K-ras mutation or showed lack of hMLH1 expression, as depicted in figure 1. Truncating as well as missense APC mutations and activating K-ras mutations were relatively common. Truncating APC mutations alone and activating K-ras mutations in codons 12 and 13 only, occurred at similar frequencies (20% (130/656) and 18% (121/656), respectively). A combination of a truncating mutation in APC and an activating mutation in K-ras occurred less often than the sole occurrences of mutations in both genes. However, as shown in table 2, the simultaneous occurrence of mutations in both genes occurred more frequently than expected on the basis of chance alone. A chi2 test for the occurrence of a truncating APC mutation and an activating K-ras mutation revealed that the occurrence of these mutations was not independent (chi2 = 8.7, P < 0.001), but the correlation was weak (Cramers V = 0.138). Finally, although 11 tumours that harboured a mutation in the APC or K-ras gene also lacked hMLH1 expression, hMLH1 deficiency occurred more frequently in tumours that did not harbour these mutations (chi2 = 36.6, P < 0.001).
###end p 43
###begin p 44
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 180 182 180 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 351 353 351 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 553 555 553 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 646 648 646 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 711 712 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
With respect to the localisation in the colorectal tract, tumours of the rectosigmoid and rectum more frequently harboured truncating APC mutations when compared to colon tumours (P = 0.001), as shown in table 3. Rectosigmoid and rectal tumours have a relatively higher frequency of K-ras mutations in codons 12 and 13 when compared to colon tumours (P = 0.05) (Table 3). Nine per cent of tumours showed hMLH1 deficiency, as determined by immunohistochemistry (Figure 2). Tumours lacking hMLH1 expression occur almost exclusively in the proximal colon (P < 0.001) and relatively more frequently show poor differentiation or are undifferentiated (P < 0.001) when compared to tumours with hMLH1 expression (Table 3).
###end p 44
###begin p 45
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 434 436 434 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 537 539 537 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 632 634 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 22 29 <span type="species:ncbi:9606">patient</span>
###xml 222 230 <span type="species:ncbi:9606">Patients</span>
###xml 413 416 <span type="species:ncbi:9606">men</span>
Next, we compared the patient and tumour characteristics of tumours harbouring a truncating APC and/or an activating K-ras mutation to those of tumours without hMLH1 expression, and these results are presented in table 4. Patients harbouring hMLH1 deficient tumours were slightly older when diagnosed with colorectal cancer (69.3 yr (68.0-70.5) versus 67.8 (67.4-68.3), P = 0.03), were relatively less frequently men (40% versus 58%, P = 0.02). Tumours without hMLH1 expression occurred relatively more frequently in the proximal colon (P < 0.001) and relatively more frequently showed poor differentiation or are undifferentiated (P < 0.001).
###end p 45
###begin p 46
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 193 195 193 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 261 263 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 318 320 318 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
When comparing tumours with a missense (but not a truncating) mutation in APC to tumours with a truncating mutation in APC, missense mutations occurred relatively more frequently in the colon (P = 0.002), less often also harboured an activating K-ras mutation (P = 0.004), and more often also lacked hMLH1 expression (P < 0.001). No differences were observed with regard to age at diagnosis, gender, Dukes' stage or tumour differentiation (data not shown).
###end p 46
###begin p 47
Finally, to assess agreement between hMLH1 expression and microsatellite instability, both hMLH1 expression and BAT-26 were analysed in 162 tumours. All tumours that had normal BAT-26, also showed hMLH1 expression. Fourteen tumours with unstable BAT-26 also lacked hMLH1 expression, and two tumours with unstable BAT-26 were found to express hMLH1, which demonstrates a high agreement between these molecular features of mismatch repair deficiency.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 232 239 232 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 420 424 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 452 458 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 578 582 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 586 592 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 717 721 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 724 730 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 972 976 969 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 983 989 980 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 754 762 <span type="species:ncbi:9606">Patients</span>
###xml 835 840 <span type="species:ncbi:9606">women</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
In this study, the occurrence of mutations in the APC, CTNNB1 and K-ras genes as well as expression of the hMLH1 protein in tumour tissue of 656 sporadic colorectal cancer cases were investigated. The occurrence of mutations in the CTNNB1 gene, which codes for beta-catenin, was rare: only five of 464 tumours analysed were found to have a mutation at one of the phosphorylation sites in exon 3. Truncating mutations in APC and activating mutations in K-ras appeared to occur at similar frequencies. Although tumours harbouring both mutations were relatively rare, mutations in APC and K-ras seemed to occur co-dependently. Nine percent of all tumours (58/656) lacked hMLH1 expression, and in these tumours almost no APC or K-ras mutations was detected. Patients harbouring a tumour with absent hMLH1 expression were older, more often women, more often had proximal colon tumours that showed poorer differentiation when compared to patients who harboured a tumour with an APC and/or K-ras mutation.
###end p 49
###begin p 50
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 651 655 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 677 683 677 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 1141 1147 1141 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 1204 1210 1204 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
The selection of patients included in this study was based on the completeness of analyses of both APC and K-ras genes as well as hMLH1 expression and this led to a considerable reduction in the number of cases that could be included in the analyses presented in this study. The largest reduction (72 cases) was due to incompleteness of the analysis of all fragments comprising the APC mutation cluster region. Tumour DNA was derived from formalin-fixed, paraffin-embedded tumour tissue blocks. Depending on the conditions of fixation and storage, the extracted DNA is more or less fragmented, which may have impaired the analysis of mutations in the APC gene more than in the K-ras gene, since the analysis of the latter is based on the amplification of a smaller gene fragment. It should be emphasized that characteristics of patients (age, sex, family history of colorectal cancer) and tumours (sub-localisation, Dukes' stage and differentiation) of the group under study are similar to the 737 patients for whom tumour material was available and to all 819 patients initially recognized within the cohort (data not shown). Moreover, the K-ras and hMLH1data presented here are similar to the data for K-ras and hMLH1 based on the complete groups (737 and 724 cases, respectively) (data not shown).
###end p 50
###begin p 51
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 811 818 811 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
Mutations in exon 3 of the CTNNB1 gene leading to loss of one of the phosphorylation sites were rare. Strikingly, all five of these mutations occurred in the proximal colon and three of these also had absent hMLH1 expression. This may indicate that these proximal colon tumours, which often also show mismatch repair deficiency, are more likely to harbour CTNNB1 mutations. This was also found in a study of microsatellite instable colorectal tumours [26]. The WAVE screening technique has not been used previously for formalin-fixed, paraffin-embedded tissue, and therefore it seems plausible that samples harbouring a CTNNB1 mutation have escaped detection. However, all 58 hMLH1 deficient samples were analysed by direct sequencing without a prior screening step, and only three of these samples harboured a CTNNB1 mutation, indicating the low frequency of such mutations.
###end p 51
###begin p 52
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 485 488 485 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 804 808 804 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 812 818 812 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 873 877 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 881 887 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 933 938 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The model describing the accumulation of genetic alterations of the APC, K-ras, TP53 and SMAD4 genes that drive the development of a carcinoma, has become generally accepted as a paradigm for the genetic basis of colorectal carcinogenesis [3,32]. The relatively low frequency of simultaneous occurrence of mutations in both APC and K-ras observed in this study seems to argue against this synergy. This contention is in accordance with observations from another cohort study, in which APC, K-ras and TP53 gene mutations were studied in 109 tumours and these mutations were found to rarely occur together in the same tumour [9]. However, the simultaneous occurrence of APC and K-ras mutations observed in our study occurs more frequently than expected based on chance alone and therefore mutations in the APC and K-ras genes do not seem to occur independently. When data on APC and K-ras mutations are derived from the study by Smith et al. [9], similar results, although not statistically significant, could be obtained.
###end p 52
###begin p 53
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
The K-ras mutation frequency of 37% is in accordance with reported frequencies of 30 to 60% [33-43]. The frequency of 37% of truncating mutations in the mutation cluster region of APC in this study, however, seems low in comparison to the general assumption that most colorectal tumours harbour a mutation in the APC gene. When only reports from studies on sporadic rather than familial colorectal cancer or colorectal cancer cell lines are considered, the mutation frequencies are lower and vary between 30 and 70% [17,44-49], and a population-based case-control study in the Netherlands reported a 32% mutation frequency [50].
###end p 53
###begin p 54
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
The method for mutation analysis of the APC mutation cluster region and exon 1 of K-ras is based on nested amplification and direct sequencing of purified PCR fragments, a highly sensitive method. Since no screening step was performed prior to the sequencing of the gene fragments, it is unlikely that mutations would have escaped detection. The reproducibility of the applied assays was good, with a reproducibility of 85% and 88% for APC and K-ras, respectively. Arguably, this indicates the extent of heterogeneity present in the tumour samples.
###end p 54
###begin p 55
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 342 344 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 421 425 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 539 541 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 325 332 <span type="species:ncbi:9606">patient</span>
In 103 sporadic colorectal cancers no alterations were found in the K-ras, APC or hMLH1 genes. It is plausible that these tumours have harboured mutations in other components of the Wnt signalling pathway, e.g. mutations in the Axin genes, which are essential for the degradation of beta-catenin, and were observed in 11% of patient samples [51]. In addition, an epi-genetic change, i.e. promotor hypermethylation of the APC gene that leads to impaired APC function has been observed in 18% of sporadic colorectal adenomas and carcinomas [52].
###end p 55
###begin p 56
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression.
###end p 56
###begin p 57
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 713 717 713 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate.
###end p 57
###begin p 58
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25].
###end p 58
###begin title 59
Conclusion
###end title 59
###begin p 60
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
In conclusion, this study shows that mutations in the CTNNB1 gene are presumably of minor importance in sporadic colorectal cancer. Although APC and K-ras mutations are often observed seperately in a tumour, these mutations seem to also occur in a co-dependent manner. Tumours that display mismatch repair deficiency, may form a distinct sub-group as they differ from tumours with APC and/or K-ras mutations with regard to age, sex, tumour sub-localisation and differentiation.
###end p 60
###begin title 61
List of abbreviations used
###end title 61
###begin p 62
APC: adenomatous polyposis coli
###end p 62
###begin p 63
TP53: tumour protein 53
###end p 63
###begin p 64
K-ras: Kirsten ras
###end p 64
###begin p 65
###xml 7 12 <span type="species:ncbi:9606">human</span>
hMLH1: human mut-L homologue 1
###end p 65
###begin p 66
NLCS: Netherlands Cohort Study on diet and cancer
###end p 66
###begin p 67
NCR: Netherlands Cancer Registry
###end p 67
###begin p 68
PALGA: Pathologisch Anatomisch Landelijk Geautomatiseerd Archief
###end p 68
###begin p 69
HE: haematoxylin and eosin
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The authors declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 400 404 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 408 414 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
ML participated in the study design, carried out the statistical analysis, interpreted the data, and drafted the manuscript. MPW conceived the study, and participated in its design and coordination, and revised the manuscript. PAW carried out the immunohistochemistry of hMLH1 and critically reviewed the manuscript. AMS carried out the beta-catenin analysis. GMJMR carried out DNA isolation and the APC and K-ras analyses. GNPvM participated in the study coordination and critically reviewed the manuscript. APdB evaluated the tissue samples for tumour content and critically reviewed the manuscript. PAvdB conceived the study, and participated in its design and coordination and critically reviewed the manuscript. AFPMdG conceived the study, and participated in its design and coordination, and revised the manuscript. All of the authors have read and approved the final manuscript.
###end p 73
###begin title 74
Pre-publication history
###end title 74
###begin p 75
The pre-publication history for this paper can be accessed here:
###end p 75
###begin p 76

###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
We are indebted to Prof. Dr. J.W. Arends for his participation in the initial phase of this study; M. Brink for tissue collection; M. Lentjes, S. Derks, H. Braam, and G. van Wijhe for laboratory assistance; Dr. M. van Engeland, Dr. L. Schouten, S. van de Crommert, H. Brants, J. Nelissen, C. de Zwart, M. Moll, W. van Dijk, M. Jansen, and A. Pisters for assistance; and H. van Montfort, T. van Moergastel, L. van den Bosch, and R. Schmeitz for programming assistance. We wish to thank the regional cancer registries (IKA, IKL, IKMN, IKN, IKO, IKR, IKST, IKW, IKZ), and the Dutch nationwide network and registry of histo- and cytopathology (PALGA). Finally, we would like to thank the departments of pathology of the following hospitals for providing the tissue blocks: Academisch Ziekenhuis Nijmegen Sint Radboud, Academisch Ziekenhuis Groningen, Rijnland Ziekenhuis, Antoni van Leeuwenhoek Ziekenhuis, Academisch Ziekenhuis Rotterdam, Stichting Laboratorium Pathologie Oost Nederland, Pathologisch Instituut Utrecht, Ziekenhuis Rijnstate Arnhem, Laboratorium Volksgezondheid Leeuwarden, Ziekenhuis Bethesda, Stichting Samenwerkend Ziekenhuizen Oost Groningen, Martini Ziekenhuis Groningen, Samenwerkend Stichting Delftse Ziekenhuizen, Leyenburg Ziekenhuis, Academisch Ziekenhuis Vrije Universiteit, Academisch Medisch Centrum, Sint Franciscus Ziekenhuis, Dr. Daniel den Hoed Kliniek, Academisch Ziekenhuis Maastricht, Goudse Ziekenhuizen Stichting Laboratorium, Canisius Wilhelmina Ziekenhuis, Slootervaart Ziekenhuis, Maaslandziekenhuis, Atrium Heerlen, Atrium Kerkrade and Brunssum, Microbiologie St. Medische Stedendriehoek, IJsselmeer Ziekenhuizen, Ziekenhuis Centrum Apeldoorn, Isala Klinieken, Elkerliekziekenhuis, Groot Ziekengasthuis, Ziekenhuis Gooi Noord, Medisch Centrum Alkmaar, Regionaal Pathologisch en Cytologisch Laboratorium voor Eemland en Noord-West Veluwe, Diakonesse Ziekenhuis, Sint Antonius Ziekenhuis, Onze Lieve Vrouwe Gasthuis, St. Lucas Andreas Ziekenhuis, Pathologisch Anatomisch Laboratorium SPALK, Ziekenhuis de Heel, Diakonessenhuis, Rode Kruis Ziekenhuis, Ziekenhuis Bronovo, Laurentius Ziekenhuis Roermond, Pathologisch Anatomisch Laboratorium Dordrecht, Zuiderziekenhuis, Sint Clara Ziekenhuis, Medisch Centrum Haaglanden, St. Streeklaboratorium Zeeland, Sint Elisabeth Ziekenhuis, Catharinaziekenhuis, Sint Maartensgasthuis and Spaarne Ziekenhuis. This work was supported by the Netherlands Organisation for Scientific Research and the Dutch Cancer Society.
###end p 78
###begin article-title 79
The hallmarks of cancer
###end article-title 79
###begin article-title 80
Cancer genes and the pathways they control
###end article-title 80
###begin article-title 81
A genetic model for colorectal tumorigenesis
###end article-title 81
###begin article-title 82
APC, signal transduction and genetic instability in colorectal cancer
###end article-title 82
###begin article-title 83
Linking colorectal cancer to Wnt signaling
###end article-title 83
###begin article-title 84
Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene
###end article-title 84
###begin article-title 85
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer
###end article-title 85
###begin article-title 86
###xml 17 22 <span type="species:ncbi:9606">human</span>
ras oncogenes in human cancer: a review
###end article-title 86
###begin article-title 87
Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer
###end article-title 87
###begin article-title 88
###xml 25 30 <span type="species:ncbi:9606">human</span>
Genetic instabilities in human cancers
###end article-title 88
###begin article-title 89
DNA methylation and genetic instability in colorectal cancer cells
###end article-title 89
###begin article-title 90
Eukaryotic DNA mismatch repair
###end article-title 90
###begin article-title 91
Clues to the pathogenesis of familial colorectal cancer
###end article-title 91
###begin article-title 92
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences
###end article-title 92
###begin article-title 93
Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein
###end article-title 93
###begin article-title 94
APC mutations in colorectal tumors with mismatch repair deficiency
###end article-title 94
###begin article-title 95
Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer
###end article-title 95
###begin article-title 96
Alternative genetic pathways in colorectal carcinogenesis
###end article-title 96
###begin article-title 97
Colorectal cancer with and without microsatellite instability involves different genes
###end article-title 97
###begin article-title 98
Pathogenesis of non-familial colorectal carcinomas with high microsatellite instability
###end article-title 98
###begin article-title 99
Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors
###end article-title 99
###begin article-title 100
Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history
###end article-title 100
###begin article-title 101
Microsatellite instability in cancer of the proximal colon
###end article-title 101
###begin article-title 102
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1
###end article-title 102
###begin article-title 103
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
###end article-title 103
###begin article-title 104
Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway
###end article-title 104
###begin article-title 105
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
###end article-title 105
###begin article-title 106
APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study
###end article-title 106
###begin article-title 107
A large-scale prospective cohort study on diet and cancer in The Netherlands
###end article-title 107
###begin article-title 108
Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research
###end article-title 108
###begin article-title 109
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines
###end article-title 109
###begin article-title 110
Lessons from hereditary colorectal cancer
###end article-title 110
###begin article-title 111
###xml 50 57 <span type="species:ncbi:9606">patient</span>
K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location
###end article-title 111
###begin article-title 112
###xml 79 84 <span type="species:ncbi:9606">human</span>
Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors
###end article-title 112
###begin article-title 113
The type of K-ras mutation determines prognosis in colorectal cancer
###end article-title 113
###begin article-title 114
Animal products and K-ras codon 12 and 13 mutations in colon carcinomas
###end article-title 114
###begin article-title 115
Ki-ras mutations and prognosis in colorectal cancer
###end article-title 115
###begin article-title 116
Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population
###end article-title 116
###begin article-title 117
###xml 61 66 <span type="species:ncbi:9606">human</span>
Type and number of Ki-ras point mutations relate to stage of human colorectal cancer
###end article-title 117
###begin article-title 118
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study
###end article-title 118
###begin article-title 119
Genetic heterogeneity in sporadic colorectal adenomas
###end article-title 119
###begin article-title 120
###xml 112 120 <span type="species:ncbi:9606">patients</span>
A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients [published erratum appears in Int J Cancer 1996 Aug 22;69(4):355]
###end article-title 120
###begin article-title 121
###xml 69 74 <span type="species:ncbi:9606">human</span>
Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia
###end article-title 121
###begin article-title 122
Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas
###end article-title 122
###begin article-title 123
###xml 29 34 <span type="species:ncbi:9606">human</span>
Mutations of the APC gene in human sporadic colorectal cancers
###end article-title 123
###begin article-title 124
Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors
###end article-title 124
###begin article-title 125
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene
###end article-title 125
###begin article-title 126
APC mutations occur early during colorectal tumorigenesis
###end article-title 126
###begin article-title 127
###xml 95 100 <span type="species:ncbi:9606">human</span>
Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers
###end article-title 127
###begin article-title 128
Dietary factors and truncating APC mutations in sporadic colorectal adenomas
###end article-title 128
###begin article-title 129
Detection of point mutations of the Axin1 gene in colorectal cancers
###end article-title 129
###begin article-title 130
###xml 68 73 <span type="species:ncbi:9606">human</span>
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
###end article-title 130
###begin article-title 131
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
###end article-title 131
###begin article-title 132
###xml 133 138 <span type="species:ncbi:9606">human</span>
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
###end article-title 132
###begin article-title 133
Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability
###end article-title 133
###begin article-title 134
BAT-26 identifies sporadic colorectal cancers with mutator phenotype: a correlative study with clinico-pathological features and mutations in mismatch repair genes
###end article-title 134
###begin article-title 135
Inverse Relationship between Microsatellite Instability and K-ras and p53 Gene Alterations in Colon Cancer
###end article-title 135
###begin article-title 136
Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability
###end article-title 136
###begin title 137
Figures and Tables
###end title 137
###begin p 138
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Distribution of aberrations in the APC and K-ras genes and hMLH1 expression in 656 colorectal tumours. The data in this figure are based on tumours from 656 sporadic colorectal cancer patients. The bars representing the different molecular alterations represent mutually exclusive groups of tumours. The category "Other" includes; APC silent mutation (n = 25), K-ras mutations other than missense mutations in codons 12 and 13 (n = 2), and both of these (n = 1).
###end p 138
###begin p 139
hMLH1 immunohistochemistry. Present (top panel) and absent (bottom panel) immunohistochemical staining for hMLH1.
###end p 139
###begin p 140
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 15 22 <span type="species:ncbi:9606">patient</span>
Description of patient, tumour and molecular characteristics of colorectal cancers harbouring a CTNNB1 mutation.
###end p 140
###begin p 141
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
a Tumours of 464 sporadic colorectal cancer patients were analysed.
###end p 141
###begin p 142
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
b 58 Tumours were selected based on absence of hMLH1 expression, 411 tumours studied were selected based on absence of a truncating APC mutation.
###end p 142
###begin p 143
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
c Two patients (numbers 6 and 7) harboured a CTNNB1 mutation that would not lead to loss of a known phosphorylation site.
###end p 143
###begin p 144
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Crosstabulation of patients with and without activating K-ras and truncating APC mutation(s).
###end p 144
###begin p 145
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 37 39 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 46 48 44 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
a Expected based on chance alone. chi2 = 8.7, P < 0.001
###end p 145
###begin p 146
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Comparisons between patients with or without a K-ras or APC mutation and hMLH1 expression.
###end p 146
###begin p 147
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
a APC mutations: only mutations resulting in a stop codon.
###end p 147
###begin p 148
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 2 8 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
b K-ras mutations: only activating mutations in codon 12 or 13.
###end p 148
###begin p 149
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
c Tumour sublocalisation, Dukes's stage and differentiation gave rise to missing values.
###end p 149
###begin p 150
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Comparisons between patients with an APC and/or K-ras mutation and absent hMLH1 expression.
###end p 150
###begin p 151
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 2 10 <span type="species:ncbi:9606">Patients</span>
a Patients with both absent hMLH1 expression and an APC or K-ras mutation were excluded from the analysis.
###end p 151
###begin p 152
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
b APC mutations: only mutations resulting in a stop codon.
###end p 152
###begin p 153
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 2 8 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
c K-ras mutations: only activating mutations in codon 12 or 13.
###end p 153

